Search

Your search keyword '"Peniket, Andy"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Peniket, Andy" Remove constraint Author: "Peniket, Andy"
45 results on '"Peniket, Andy"'

Search Results

2. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial

3. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

5. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study

8. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

9. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

12. Post-Transplant MRD Status and T Cell Chimerism Predict Outcomes in Patients Allografted for AML/MDS-a Prospective Analysis from the UK NCRI Figaro Trial

13. Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy

15. Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms

17. Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience

18. Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy.

19. A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?

20. Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma—a retrospective study from the BSBMT (BEAM versus LEAM)

21. Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy

22. Genomic surveillance of Escherichia coli and Klebsiella spp. in hospital sink drains and patients

23. Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care

24. Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia

26. Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

27. The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

28. Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts

30. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

31. Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience.

33. Treatment stratification of respiratory syncytial virus infection in allogeneic stem cell transplantation

34. Impact of graft‐versus‐lymphoma effect on outcomes after reduced intensity conditioned‐alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies

35. A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?

37. Role of HLA-Bexon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study

38. Impact of graft‐versus‐lymphoma effect on outcomes after reduced intensity conditioned‐alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.

40. Reduced‐intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

44. An innovative method to generate a Good Manufacturing Practice--ready regulatory T-cell product from non-mobilized leukapheresis donors.

45. Selective depletion of FOXP3high cells by Fas–Fas-L–induced apoptosis occurs in CD4+CD25+-enriched populations during repeated expansion.

Catalog

Books, media, physical & digital resources